Journal List > Korean J Urol > v.48(5) > 1004920

Bak, Yoon, and Chung: Effects of an α-blocker and Terpene Mixture for Pain Control and Spontaneous Expulsion of Ureter Stone



It was known that α-1 receptors are present in ureteral smooth muscle. We aimed to reveal the effect of an α-blocker (tamsulosin) and terpene mixture (Rowatinex®) on the expulsion of ureter stone (size less than 1cm), as well as its affect on the relief of pain.

Materials and Methods

The patients were classified into group A in which the size of the ureter stone less than 4mm (144 subjects) and group B in which the size of stone was between 4mm and 10mm (48 patients). Each study group was also further divided into 3 sub-groups: group 1 with analgesics only, group 2 with Rowatinex® as well as analgesics, and group 3 with 0.4mg of tamsulosin as well as analgesics.


It was shown that the expulsion rates of ureter stone in sub-group 1 of group A, at the end of first week, was statistically lower (p<0.05) compared to that of sub-group 2 with Rowatinex®. It was also shown that compared to sub-group 1, the expulsion rate of ureter stone at the end of first week in sub-group 3 was statistically significant (p<0.05). Compared to the consumed amount of analgesics in group A, it was revealed that sub-group 2 and sub-group 3 used statistically fewer ampules of than sub-group 1 (p<0.05).


Our study clearly showed that both α-blocker and Rowatinex® are effective means of controlling colicky pain and they speed up excretion of ureter stones that are less than 4mm in size, at the end of first week. Therefore, we conclude that an alpha-blocker and Rowatinex® should be considered as an adjuvant regimen and this is beneficial for patients with ureter stone less than 4mm in size.

Figures and Tables

Table 1
Characteristics of groups A and B

*Group 1: ketorolac tromethamine (Tarasyn®), Group 2: ketorolac tromethamine (Tarasyn®)+Rowatinex®, Group 3: ketorolac tromethamine (Tarasyn®)+tamsulosin (Harnal®), §Group A: stone size (less than 0.4cm), Group B: stone size (0.4-1cm)

Table 2
Stone location

Group 1 vs. Group 2 (p>0.05), Group 1 vs. Group 3 (p>0.05), Group 2 vs. Group 3 (p>0.05), chi-square test

Table 3
Expulsion rate of ureter stone

Group A: *Group 1 vs. Group 2 (p<0.05), Group 1 vs. Group 3 (p<0.05), Group 2 vs. Group 3 (p>0.05), Group 1 vs. Group 2 (p>0.05), Group 1 vs. Group 3 (p<0.05), Group 2 vs. Group 3 (p<0.05), Group B: Group 1 vs. Group 2 (p>0.05), Group 1 vs. Group 3 (p>0.05), Group 2 vs. Group 3 (p>0.05), chi-square test

Table 4
Injective analgesic use of each group

*Group A: Group 1 vs. Group 2 (p>0.05), Group 1 vs. Group 3 (p>0.05), Group 2 vs. Group 3 (p>0.05), Group A: Group 1 vs. Group 2 (p<0.05), Group 1 vs. Group 3 (p<0.05), Group 2 vs. Group 3 (p>0.05), chi-square test


1. Yilmaz E, Batislam E, Basar MM, Tuglu D, Ferhat M, Basar H. The comparison and efficacy of 3 different a-1 adrenergic blockers for distal ureter stones. J Urol. 2005. 173:2010–2012.
2. Ehreth JT, Drach GW, Arnett ML, Barnett RB, Govan D, Lingelman J, et al. Extracorporeal shock wave lithotripsy: multicenter study of kidney and upper ureter versus middle and lower ureter treatments. J Urol. 1994. 152:1379–1385.
3. KIM KH, Shim BS. The comparison of efficacy of ureteroscopic removal and shock wave lithotripsy in lower ureteral stone. Korean J Urol. 2001. 42:905–909.
4. Menon M, Resnick MI. Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Urinary lithiasis: etiology, diagnosis, and medical treatment. Campbell's urology. 2002. 8th ed. Philadelphia: Saunders;3227–3292.
5. Hubner WA, Irby P, Stoller ML. Natural history and current concepts for the treatment of small ureteral calculi. Eur Urol. 1993. 24:172–176.
6. Han MC, Park YY, Shim BS. Efficacy of tamsulosin on the expectant treatment of lower ureteral stones. Korean J Urol. 2006. 47:708–711.
7. Miller OF, Kane CJ. Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol. 1999. 162:688–691.
8. Porpiglia F, Destefanis P, Fiori C, Fontana D. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology. 2000. 56:579–582.
9. Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM. Nifedifine versus tamsulosin for the management of lower ureteral stones. J Urol. 2004. 172:568–571.
10. Hussain Z, Inman RD, Elves AW, Shipstone DP, Ghiblawi S, Coppinger SW. Use of glyceryl trinitrate patches in patients with ureteral stones: a randomizes, double-blind, placebo-controlled study. Urology. 2001. 58:521–525.
11. Porpiglia F, Destefanis P, Fiori C, Scapa RM, Fontana D. Role of adjunctive medical therapy with nifedipine and deflazacort after shock wave lithotripsy of ureteral stones. Urology. 2002. 59:835–838.
12. Shoekeir AA. Renal colic: pathophysiology, diagnosis and treatment. Eur Urol. 2001. 39:241–249.
13. Morita T, Wada I, Saeki H, Tsuchida S, Weiss RM. Ureteral urine transport: changes in bolus volume, peristaltic frequency, intraluminal pressure and volume of flow resulting from autonomic drugs. J Urol. 1987. 137:132–135.
14. Obara K, Takeda M, Shimura H, Kanai T, Tsutsui T, Komeyama T, et al. Alpha-1 adrenoreceptor subtypes in the human ureter: characterization by RT-PCR and in situ hybridization. J Urol. 1996. 155:Suppl. 472A. abstract 646.
15. Siller G. Effect of rowatinex capsules on the stone fragments formed by extracorporeal shock-wave lithotripsy. Magyar Urol. 1998. 10:139–146.
16. Lee CB, Ha US, Lee SJ, Kim SW, Cho YH. Preliminary experience with a terpene mixture versus ibuprofen for treatment of category III chronic prostatitis/chronic pelvic pain syndrome. World J Urol. 2006. 24:55–60.
17. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol. 2005. 174:167–172.
18. Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. 2003. 170:2202–2205.
Similar articles